Diagnosis

ASCO’s living guideline covers treatment across the myeloma pathway. This update focuses on relapsed or refractory myeloma, recommending ciltacabtagene autoleucel and teclistamab plus daratumumab as preferred options at first relapse for eligible patients who have not previously received BCMA-directed treatment.

Read the British Society for Haematology guideline on early diagnosis of AL amyloidosis, including when to suspect it and when urgent haematology review may be needed.

Wales-adapted myeloma diagnostic tool to support GPs with recognising symptoms, interpreting tests and making timely referrals.

Welsh-language myeloma diagnostic tool for primary care, with guidance on tests, interpretation and referral.

Developed by Myeloma Patients Europe (MPE), this visual pathway outlines key signs, symptoms and investigations to support early diagnosis of AL amyloidosis.

As part of the Race Equality Foundation partnership project with Myeloma UK, a series of posters have been co-produced with people living with myeloma, carers and healthcare professionals.

The International Myeloma Society and International Myeloma Working Group have published updated consensus recommendations on the definition of high-risk myeloma.

The UKONS 24-Hour Triage Rapid Assessment and Access Toolkit (v3) provides a standardised, symptom-based risk assessment process for acute oncology and haematology telephone triage. Using a Red–Amber–Green (RAG) scoring system, it helps healthcare professionals prioritise patients and guide safe, timely care.

The IMPEDE-VTE calculator is an evidence-based tool for assessing venous thromboembolism (VTE) risk in people with myeloma. It combines patient and treatment factors to guide prevention, monitoring, and clinical decision-making.

The paper outlines a consensus approach to diagnosis, treatment and monitoring of MGRS, including guidance on the investigations required to confirm the condition, principles of supportive care, and haematological treatment strategies. It also highlights the need for ongoing multidisciplinary collaboration in managing this rare but clinically important disorder.